Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours

Bone Marrow Transplantation

Volumn 43, Issue 12, 2009, Pages 927-934

  Willis, F ^a   Woll, P ^b,c   Theti, D ^a   Jamali, H ^a   Bacon, P ^d   Baker, N ^e   Pettengell, R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d AMGEN INC   (United States)

^e AMGEN LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE PAIN; CANCER GROWTH; CD34+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; STEM CELL MOBILIZATION; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; CELL COUNT; DISEASE PROGRESSION; DRUG TOXICITY; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649870284     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.411     Document Type: Article

References (23)

1. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood cells. J Am Soc Hematol 1997; 89: 2233-2258.
2. + cell dose in blood transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Filshie RJA. Cytokines in haemopoietic progenitor mobilization for peripheral blood stem cell transplantation. Curr Pharm Des 2002; 8: 379-394.
5. Biganzoli L, Untch M, Skacel T, Pico J-L. Neulasta (pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004; 31 (Suppl 8): 27-34.
6. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30 (Suppl 13): 24-30.
7. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
8. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage II/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
9. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. A randomized double-blind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
10. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10: 715-724.
11. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dosefinding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
12. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R et al. Open-label randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503-1508.
13. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al. Randomized, multi-center, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
14. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005; 27: 449-451.
15. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 889-893.
16. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522-2528.
17. Isidorins A, Tani M, Binifazi F, Zinzani P, Curti A, Motta MR et al Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
18. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
19. -). Haematol J 2004; 5: S51 (Abstract 148).
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-36.
21. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen H, del Canizo M et al. Lymphoma phase II pilot study of pegfilgrastim and Filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-412.
22. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modelling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46: 747-757.
23. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007; 27: 1387-1393.